Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Journal: Breast cancer research and treatment
Published: August 13, 2021
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Journal: The oncologist
Published: July 20, 2021
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 01, 2021
DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings.
Journal: JNCI cancer spectrum
Published: January 11, 2021
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Journal: Clinical lung cancer
Published: July 22, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 01, 2020
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704.
Journal: International journal of radiation oncology, biology, physics
Published: February 07, 2020
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Journal: The oncologist
Published: March 22, 2019
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance).
Journal: Therapeutic advances in medical oncology
Published: March 21, 2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 25, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal: JCO precision oncology
Published: January 04, 2019
Last Updated: 09/26/2026